Trials / Recruiting
RecruitingNCT07366866
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci136 for Injection in Healthy Adult Participants in China.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GenSci136 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2026-03-16
- Primary completion
- 2027-02-07
- Completion
- 2027-03-09
- First posted
- 2026-01-26
- Last updated
- 2026-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07366866. Inclusion in this directory is not an endorsement.